Cardiovascular Safety of non-insulin Anti-hyperglycemic Therapies

Cardiovascular Safety of non-insulin Anti-hyperglycemic Therapies

Mojtaba Mehrdad

As a modified lecture of Dr.Farzad Hadaegh,

With a lot of thanks

Disclosures

• Relationships with Commercial Interests: None
• Disclosure of Commercial Support : None
• Potential for Conflict(s) of Interest: None

Agenda

Overview diabetes and CHD in Tehran

Metformin

Insulin secretoguges

TZDs

 DPP4 inhibitors

GLP1 analouges, SGLT2 inhibitors, Changing the landscape of diabetes

Choice of second line medication after Metformin

Take home Message

• Type 2 diabetes is associated with excess vascular disease and premature mortality.
• In recent years, the United States Food and Drug Administration, the body responsible for evaluating the safety and efficacy of medicines in the United States, has required data from large prospective trials to assess the safety of new glucose-lowering drugs on cardiovascular outcomes.
• Interpreting these trials is complicated by substantial differences in their design, the populations studied and data analysis.